Overview

A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Phase:
Phase 3
Details
Lead Sponsor:
Clarus Therapeutics, Inc.
Collaborators:
INC Research
Syneos Health
Treatments:
Methyltestosterone
Pharmaceutical Solutions
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate